{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-129750","form_type":"8-K","ticker":"CVSI","cik":"0001510964","company_name":"CV Sciences, Inc.","filed_at":"2024-11-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.640971+00:00","generated_at":"2026-05-29T20:39:34.510247+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CV Sciences agrees to acquire Extract Labs for $1.4M cash and stock, plus earnout","bullets":["Total consideration: $400K cash + $1M in CVSI stock at closing; up to $600K earnout in stock.","Earnout tied to Extract Labs revenue targets: $3.5M-$4.6M per 12-month period for two years.","Acquisition expected to close in Q1 2025, subject to customary conditions.","CV Sciences plans to in-source +PlusCBD production, citing cost savings and supply chain control.","Extract Labs described as stand-alone profitable, GMP-certified, and FDA-registered."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-129750","json":"https://secwatch.observer/filing/0000950170-24-129750.json","markdown":"https://secwatch.observer/filing/0000950170-24-129750.md","text":"https://secwatch.observer/filing/0000950170-24-129750.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1510964/000095017024129750/0000950170-24-129750-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1510964/000095017024129750/cvsi-20241115.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T20:39:34.510247+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}